Roth Capital Boosts PT on Keryx (KERX) to $24; Recommends Buying Into ASN Meeting
Tweet Send to a Friend
Roth Capital raises its price target on Buy-rated Keryx Biopharmaceuticals (Nasdaq: KERX) from $16 to $24 today.
Analyst Joseph ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst Joseph ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
